The purposes of this study are:

• To estimate the incidence of serious adverse experiences and adverse experiences of interest in patients with rheumatoid arthritis (RA) treated with ENBREL®;
• To systematically collect and document use patterns, effectiveness and safety of DMARD treatments currently used in the management of rheumatoid arthritis.

Inclusion Criteria:

• Fulfillment of the 1987 American Rheumatism Association criteria for RA
• Currently requiring the addition of ENBREL® therapy (to be taken alone or in addition to their current DMARD therapy)

Exclusion Criteria:

• Currently or previously enrolled in RADIUS 1
• Currently enrolled in a clinical trial where treatments or patient visits are imposed by a protocol
• Active infections
• Known allergy to ENBREL® or any of its components
• Current treatment with ENBREL®
• Patients who have previously demonstrated to be intolerant of or refractory to ENBREL® therapy
• Nursing or pregnant women